| US 7,557,129 B2 | ||
| Cyanopyridine derivatives useful in the treatment of cancer and other disorders | ||
| William J. Scott, Guilford, Conn. (US); Jacques Dumas, Bethany, Conn. (US); Stephen Boyer, Hilden (Germany); Wendy Lee, Hamden, Conn. (US); Yuanwei Chen, North Haven, Conn. (US); Barton Phillips, New Haven, Conn. (US); Sharad Verma, New Haven, Conn. (US); Jianqing Chen, New Haven, Conn. (US); Zhi Chen, Hamden, Conn. (US); Jianmei Fan, Hamden, Conn. (US); Brian Raudenbush, Charlton, Mass. (US); Aniko Redman, Derby, Conn. (US); Lin Yi, Milford, Conn. (US); Qingming Zhu, West Haven, Conn. (US); and Lila Adnane, Madison, Conn. (US) | ||
| Assigned to Bayer Healthcare LLC, Tarrytown, N.Y. (US) | ||
| Filed on Feb. 27, 2004, as Appl. No. 10/788,029. | ||
| Claims priority of provisional application 60/450323, filed on Feb. 28, 2003. | ||
| Claims priority of provisional application 60/450324, filed on Feb. 28, 2003. | ||
| Claims priority of provisional application 60/450348, filed on Feb. 28, 2003. | ||
| Prior Publication US 2004/0235829 A1, Nov. 25, 2004 | ||
| Int. Cl. A61K 31/4433 (2006.01); C07D 405/12 (2006.01) | ||
| U.S. Cl. 514—338 [546/283.7] | 18 Claims |
1. A compound of Formula (I)
![]() each R3 is independently
halogen,
R4,
OR4,
S(O)R4,
C(O)R4,
C(O)NR4R5,
oxo,
cyano or
NO2; and
R4 and R5 are independently hydrogen, C1-6alkyl, or up to per-halogenated C1-6alkyl,B is selected from the group consisting of
![]() halogen,
C1-5haloalkyl,
NO2;
C(O)NR4R5
C1-6alkyl,
C1-6dialkylamine,
C1-3alkylamine,
CN,
amino,
hydroxyl or C1-3alkoxy
SCH3,
methylsulfonyl, R4 and R5 are independently hydrogen, C1-6alkyl, or up to per-halogenated C1-6alkyl,L is O or S,m is an integer 0, 1, 2, or 3, andeach R2 is independently C1-5alkyl, C1-5haloalkyl, C1-3alkoxy, N-oxo or N-hydroxy.
|